Literature DB >> 15830475

Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

W Brumfitt, J Kosmidis, J M Hamilton-Miller, J N Gilchrist.   

Abstract

Cefoxitin, a semisynthetic cephamycin, has been compared with the widely used parenteral cephalosporin, cephalothin, in terms of antibacterial activity, human pharmacokinetics, and toxicity. For both compounds, minimal inhibitory concentrations were within the therapeutic range against the 156 gram-positive cocci tested (except group D streptococci), but cephalothin was 8 to 20 times more active. Regarding the 313 gram-negative organisms tested, both antibiotics were of approximately equal activity against cephalothin-susceptible strains, but cefoxitin was outstandingly superior against Providencia spp. and indole-producing Proteus spp., and markedly better against Serratia marcescens and Bacteroides fragilis. Against these organisms, cefoxitin but not cephalothin would be expected to be therapeutically valuable. Antibiotic activity levels in the serum and urine of 18 human volunteers after parenteral administration were higher and more prolonged in the case of cefoxitin, which had an average terminal serum half-life of about 45 min and a urinary recovery of about 90%. Cefoxitin was entirely nontoxic and, given intramuscularly, slightly less painful then cephalothin. These preliminary results suggest that cephamycins may prove to be a significant chemotherapeutic advance.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 15830475      PMCID: PMC444639          DOI: 10.1128/AAC.6.3.290

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Novel method for bioavailability assessment.

Authors:  K C Kwan; A E Till
Journal:  J Pharm Sci       Date:  1973-09       Impact factor: 3.534

2.  Pharmacokinetics of phosphonomycin in Man. I. Intravenous administration.

Authors:  K C Kwan; D A Wadke; E L Foltz
Journal:  J Pharm Sci       Date:  1971-05       Impact factor: 3.534

3.  Beta-lactam antibiotics from Streptomyces.

Authors:  R Nagarajan; L D Boeck; M Gorman; R L Hamill; C E Higgens; M M Hoehn; W M Stark; J G Whitney
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

4.  Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.

Authors:  A K Miller; E Celozzi; Y Kong; B A Pelak; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

5.  Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies.

Authors:  H Wallick; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

6.  Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin.

Authors:  J Kosmidis; J M Hamilton-Miller; J N Gilchrist; D W Kerry; W Brumfitt
Journal:  Br Med J       Date:  1973-12-15

7.  Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation.

Authors:  H R Onishi; D R Daoust; S B Zimmerman; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

8.  Cephamycins, a new family of beta-lactam antibiotics: antibacterial activity and resistance to beta-lactamase degradation.

Authors:  D R Daoust; H R Onishi; H Wallick; D Hendlin; E O Stapley
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Cephamycins, a new family of beta-lactam antibiotics. I. Production by actinomycetes, including Streptomyces lactamdurans sp. n.

Authors:  E O Stapley; M Jackson; S Hernandez; S B Zimmerman; S A Currie; S Mochales; J M Mata; H B Woodruff; D Hendlin
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

  9 in total
  26 in total

1.  Pharmacokinetic and clinical studies on cefuroxime.

Authors:  R Norrby; R D Foord; J D Price; P Hedlund
Journal:  Proc R Soc Med       Date:  1977

2.  Clinical experience in the treatment of pneumonia with cefuroxime.

Authors:  T Pettersson
Journal:  Proc R Soc Med       Date:  1977

3.  Comparative clinical pharmacology of intravenous cefoxitin and cephalothin.

Authors:  P F Sonneville; R R Kartodirdjo; H Skeggs; A E Till; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

4.  Antibacterial activity of selected beta-lactam and aminoglycoside antibiotics against cephalothin-resistant Enterobacteriaceae.

Authors:  R P Lewis; R D Meyer; L L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

5.  In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

6.  Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.

Authors:  Arantxazu Isla; Iñaki F Trocóniz; Ignacio López de Tejada; Silvia Vázquez; Andrés Canut; Jesús Muriel López; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Eur J Clin Pharmacol       Date:  2012-01-15       Impact factor: 2.953

7.  Cephamycins: a review, prospects and some original observations.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1975       Impact factor: 3.553

8.  Lysis if enterobacteria by cefoxitin, cefuroxime, and cephalothin.

Authors:  C S Goodwin; J P Hill
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

9.  The pharmacokinetics of cefuroxime after intravenous injection.

Authors:  P E Gower; C H Dash
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

10.  Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin.

Authors:  P F Sonneville; K S Albert; H Skeggs; H Gentner; K C Kwan; C M Martin
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.